GRFS vs HAE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GRFS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GRFS and HAE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GRFS and HAE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS.

Full GRFS guide

Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.

Full HAE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GRFS drivers: Immunoglobulin demand and volume growth; Margin recovery from lower cost-per-liter.
• HAE drivers: Plasma without the CSL overhang; Yield software as a razor-blade lever.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. For HAE, customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GRFS if you believe its drivers more; HAE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GRFS and HAE guides.

GRFS. As of July 2026 Grifols trades at a discount to plasma peers like CSL, reflecting its higher leverage and the residual governance overhang rather than weak operations. On enterprise-value terms the shares look inexpensive against roughly EUR 1.8 billion of adjusted EBITDA, but the large net-debt position means most of that enterprise value still sits with lenders, which is exactly why deleveraging is the key equity lever. Analysts generally rate the ADR in the Hold-to-Moderate-Buy range with price targets clustered around $10 to $12.50.

HAE. A little over three times sales is an unremarkable multiple for a medical-device company with high-margin recurring disposables, and it reflects several years in which reported growth was held down by the CSL transition rather than by demand. The August 2026 print was the first quarter in a while where reported and organic growth were the same number, which is what happens when the lost contract finally leaves the comparison. What the multiple is really pricing is whether mid single-digit organic growth is the ceiling or the floor.

Headline figures (approximate, July 2026): GRFS shows revenue (fy 2025) ~EUR 7.5 billion (~$8.2 billion), adjusted ebitda (fy 2025) ~EUR 1.8 billion (~24% margin), net profit (fy 2025) ~EUR 402 million (more than doubled YoY), q1 2026 revenue ~EUR 1.7 billion (+3.3% cc); HAE shows market cap ~$4.13B, revenue (ttm) ~$1.35B, share price ~$90.80, price / ttm sales ~3.1x.

GRFS and HAE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GRFS and HAE exposure against your real portfolio. It is not an investment adviser.